Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00158067 · ClinicalTrials.gov registry record · Phase 2

Study of an External Responsive Neurostimulator System on Epileptiform Activity

A Phase 2 study of Epilepsy, sponsored by NeuroPace.

Completed
Registry status
Phase 2
Development phase
150
Enrollment target
5
Study locations

NCT00158067: Completed Phase 2 study of Epilepsy, sponsored by NeuroPace.

NCT00158067 is a Phase 2 study of Epilepsy that has completed, run by NeuroPace. The registered enrollment target is 150 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (84% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00158067, a Phase 2 study of Epilepsy, has completed, sponsored by NeuroPace.

COMPLETED
Registry status
Phase 2
Development phase
150 participants
Enrollment target
5
Study locations

Study Summary

This feasibility clinical investigation is designed to demonstrate that the NeuroPace external Responsive Neurostimulator (model eRNS-300) can safely deliver responsive electrical stimulation automatically to affect epileptiform activity. The eRNS-300 is based on an implantable neurostimulator that has been adapted for acute, external use in a hospital setting.

Conditions Studied

Interventions

  • DEVICE external Responsive Neurostimulator (eRNS) System

Study Locations (5)

Arizona

  • Research Site - Scottsdale

Georgia

  • Research Site - Augusta

Maryland

  • Research Site - Baltimore

Minnesota

  • Research Site - Rochester

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2002-03
Est. Completion 2008-03
Phase Phase 2
NeuroPace

8 total trials

What the finished NCT00158067 record still lists

NCT00158067 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which external Responsive Neurostimulator (eRNS) System is the first listed.

NCT00158067 lists 5 locations in 5 states (Arizona, Georgia, Maryland).

Frequently Asked Questions

What is clinical trial NCT00158067 about?

NCT00158067 is a clinical study titled "Study of an External Responsive Neurostimulator System on Epileptiform Activity". This feasibility clinical investigation is designed to demonstrate that the NeuroPace external Responsive Neurostimulator (model eRNS-300) can safely deliver responsive electrical stimulation automatically to affect epileptiform activity. The eRNS-300 is based on an implantable neurostimulator that ...

What is the current status of trial NCT00158067?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2002-03. Estimated completion is 2008-03.

What conditions does trial NCT00158067 study?

This clinical trial studies the following conditions: Epilepsy.

What interventions are being tested in trial NCT00158067?

The interventions under investigation include: external Responsive Neurostimulator (eRNS) System (DEVICE).

Who is sponsoring clinical trial NCT00158067?

This trial is sponsored by NeuroPace, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00158067 being conducted?

This trial has 5 study locations across Arizona, Georgia, Maryland, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00158067's enrollment target sits among peer trials

150 40th of 160 higher than 120 of 160 other Epilepsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00158067, the US trial registry maintained by the National Library of Medicine. NCT00158067 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.